VOX vs XBI
Vanguard Communication Services ETF vs SPDR S&P Biotech ETF
- • VOX has the lower expense ratio at 0.09% vs 0.35% for XBI.
- • VOX pays a higher dividend yield (1.09%).
Side-by-side metrics
| Metric | VOX | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.09% | 0.35% |
Dividend yield Trailing 12-month yield. | 1.09% | 0.35% |
AUM Assets under management — bigger funds are typically more liquid. | $5.61B | $10.92B |
YTD return | -5.45% | 28.80% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 1.07 | 1.01 |
P/E ratio | 16.87 | — |
Last price | $184.09 | $156.41 |
Inception | — | — |
Issuer | Vanguard | State Street |
VOX top holdings
| META | Meta Platforms Inc Class A | 25.31% |
| GOOGL | Alphabet Inc Class A | 13.97% |
| GOOG | Alphabet Inc Class C | 7.70% |
| DIS | The Walt Disney Co | 4.26% |
| VZ | Verizon Communications Inc | 4.04% |
| T | AT&T Inc | 4.03% |
| NFLX | Netflix Inc | 3.77% |
| SPCX | Space Exploration Technologies Corp Class A | 2.88% |
| WBD | Warner Bros. Discovery Inc Ordinary Shares - Class A | 2.73% |
| TMUS | T-Mobile US Inc | 2.44% |
XBI top holdings
| MRNA | Moderna Inc | 2.37% |
| NTRA | Natera Inc | 1.82% |
| HALO | Halozyme Therapeutics Inc | 1.77% |
| TWST | Twist Bioscience Corp | 1.77% |
| BIIB | Biogen Inc | 1.75% |
| AMGN | Amgen Inc | 1.73% |
| EXEL | Exelixis Inc | 1.73% |
| UTHR | United Therapeutics Corp | 1.72% |
| ABBV | AbbVie Inc | 1.71% |
| GILD | Gilead Sciences Inc | 1.70% |
About VOX
VOX (Vanguard Communication Services ETF) is US communication services sector stocks. Managed by Vanguard, the fund carries $5.6B in assets under management, an expense ratio of 0.09%, a dividend yield of 1.09%. Its largest holding is Meta Platforms Inc Class A (META), which represents 25.3% of the portfolio. Real Estate is the fund's largest sector exposure at 0.1%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.35%. Its largest holding is Moderna Inc (MRNA), which represents 2.4% of the portfolio. Financial Services is the fund's largest sector exposure at 0.6%.